BMO Capital Markets reiterated their buy rating on shares of Glaukos Corporation (NYSE:GKOS) in a research report sent to investors on Wednesday. The brokerage currently has a $45.00 target price on the medical instruments supplier’s stock.

Other equities analysts have also issued research reports about the stock. BidaskClub upgraded shares of Glaukos Corporation from a hold rating to a buy rating in a report on Saturday, June 24th. Zacks Investment Research upgraded shares of Glaukos Corporation from a hold rating to a buy rating and set a $46.00 price objective on the stock in a report on Friday, July 21st. Piper Jaffray Companies reiterated a buy rating and issued a $56.00 price objective on shares of Glaukos Corporation in a report on Thursday, August 3rd. Roth Capital cut their price objective on shares of Glaukos Corporation from $60.00 to $54.00 and set a buy rating on the stock in a report on Thursday, August 3rd. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $60.00 price objective (up previously from $54.00) on shares of Glaukos Corporation in a report on Thursday, September 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. Glaukos Corporation currently has a consensus rating of Buy and an average target price of $48.57.

Glaukos Corporation (NYSE GKOS) traded down 2.65% during trading on Wednesday, reaching $32.73. The company had a trading volume of 502,296 shares. Glaukos Corporation has a 52-week low of $28.72 and a 52-week high of $52.49. The company’s market capitalization is $1.13 billion. The stock has a 50 day moving average price of $33.78 and a 200-day moving average price of $33.78.

ILLEGAL ACTIVITY WARNING: “Glaukos Corporation (GKOS) Receives Buy Rating from BMO Capital Markets” was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/glaukos-corporation-gkos-receives-buy-rating-from-bmo-capital-markets/1641824.html.

In other news, Director Orbimed Advisors Llc sold 325,000 shares of the business’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $37.93, for a total value of $12,327,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas William Burns sold 73,788 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $41.36, for a total transaction of $3,051,871.68. The disclosure for this sale can be found here. Insiders sold a total of 980,200 shares of company stock valued at $37,900,263 in the last three months. Insiders own 16.40% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Navellier & Associates Inc grew its position in shares of Glaukos Corporation by 4.9% during the 2nd quarter. Navellier & Associates Inc now owns 33,307 shares of the medical instruments supplier’s stock valued at $1,381,000 after buying an additional 1,567 shares during the last quarter. Public Employees Retirement System of Ohio grew its position in shares of Glaukos Corporation by 14.5% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 118,100 shares of the medical instruments supplier’s stock valued at $4,898,000 after buying an additional 15,000 shares during the last quarter. Koch Industries Inc. bought a new stake in shares of Glaukos Corporation during the 2nd quarter valued at about $683,000. Ameritas Investment Partners Inc. grew its position in shares of Glaukos Corporation by 93.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 1,212 shares during the last quarter. Finally, California State Teachers Retirement System grew its position in shares of Glaukos Corporation by 54.0% during the 2nd quarter. California State Teachers Retirement System now owns 50,752 shares of the medical instruments supplier’s stock valued at $2,105,000 after buying an additional 17,800 shares during the last quarter. 88.95% of the stock is owned by institutional investors and hedge funds.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Analyst Recommendations for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.